Biocon Biologics  /  News  /  Media Stories

MEDIA STORIES

Aim is to be among top three biosimilars players globally: Biocon Biologics CEO Shreehas Tambe

 27-May-2024

external_link-01
Acceleration of biosimilar business, debt reduction to be key priorities in FY25: Biocon Chief

 18-May-2024

external_link-01
Biocon’s Biosimilar Business Set For Strong Growth: CEO Shreehas Tambe

 18-May-2024

external_link-01
Biocon Biologics Signs 10-Year Deal With Eris Lifesciences To Expand Patient Access

 14-Mar-2024

external_link-01
Biocon Biologics: US Biosimilars Are A Marathon, Not A Sprint

 13-Mar-2024

external_link-01
Biocon Biologics Secures US Entry Date For Bmab 1200, A Stelara Biosimilar

 01-Mar-2024

external_link-01
Biocon included in S&P Global Sustainability Yearbook 2024

 20-Feb-2024

external_link-01
Biocon Biologics focusing on market share gains of biosimilars in key markets

 13-Feb-2024

external_link-01
We are focused on consolidating our acquired businesses for the coming fiscal year: Biocon Biologics

 12-Feb-2024

external_link-01
Biocon Biologics inks pact with Sandoz for sale of 2 biosimilar products in Australia

 09-Feb-2024

external_link-01
Budget ’24 | A vision of ‘Viksit Bharat’, driven by inclusion and innovation: Kiran Mazumdar Shaw

 02-Feb-2024

external_link-01
Biocon to commercialize biosimilars in 31 European countries

 22-Dec-2023

external_link-01
Biocon Biologics grants Sandoz exclusive rights to market biosimilar adalimumab in Japan

 22-Dec-2023

external_link-01
Biocon Biologics completes integration of Viatris’ biosimilars business

 18-Dec-2023

external_link-01
Biocon Biologics Clinches Seventh Consecutive Asia IP Elite Recognition

 15-Dec-2023

external_link-01
Taking Control Of Our Destiny: Biocon Biologics CEO Tambe Celebrates European Viatris Integration

 07-Dec-2023

external_link-01
Biocon Biologics integrates Viatris’ biosimilar biz in 31 European nations

 30-Nov-2023

external_link-01
Interview With Shreehas Tambe, MD On Biocon’s Strong Q2 Earnings And Acquisition Plans

 15-Nov-2023

external_link-01
Biocon Biologics targets top three biosimilar spot: Shreehas Tambe

 13-Nov-2023

external_link-01
Biocon Biologics receives UK regulator’s approval for ophthalmic drug YESAFILI

 13-Nov-2023

external_link-01
Biocon Biologics to sell 2 non-core branded formulations businesses to Eris Lifesciences for ₹366 cr

 08-Nov-2023

external_link-01
Kedar Upadhye steps in as new CFO of Biocon Biologics

 19-Oct-2023

external_link-01
Biocon Biologics integrates Viatris Biosimilars in North America, shares up

 07-Sep-2023

external_link-01
Biocon Biologics announces top leadership appointments

 04-Aug-2023

external_link-01
Biocon Biologics completes integration of biosimilars business in 70+ emerging markets

 05-July-2023

external_link-01
Biocon Biologics Ltd launches biosimilar HULIO in US

 05-July-2023

external_link-01
Biocon Biologics Ltd launches biosimilar HULIO in US

 05-July-2023

external_link-01
Biocon Biologics Receives EU Good Manufacturing Practice Certification

10-July-2022

external_link-01
Biocon Biologics’ antibody drug unit in Bengaluru gets EU GMP certificate

06-July-2022

external_link-01
Biocon Biologics receives EU GMP certification for its new biologics manufacturing facility in Bengaluru

 05-July-2022

external_link-01
Biocon Biologics expects big gains from integration of Viatris business, SII deal

 09-June-2022

external_link-01
Expect regulatory nods for deal with Serum and Viatris to come by H2: Kiran Mazumdar-Shaw, chairperson, Biocon and Biocon Biologics

04-May-2022

external_link-01
Biocon Biologics may close $3.34 billion Viatris deal in Q1

02-May-2022

external_link-01
Eyeing over 15% market share in US for insulin Glargine: Shreehas Tambe

30-April-2022

external_link-01
Biocon Biologics expects R&D expenses to hover between 10-15% in the next financial year

29-April-2022

external_link-01
Biocon Biologics acquires Viatris for $3.33 billion

01-Mar-2022

external_link-01
Biocon Biologics acquires Viatris’ biosimilars business in $3.3 bn deal

28-Feb-2022

external_link-01
R&D expenditure will rise in the coming quarters: Biocon Biologics MD

25-Jan-2022

external_link-01
Insulins access program for young expanded in Dec quarter: Biocon Biologics MD

24-Jan-2022

external_link-01
Biocon Biologics set to reap biosimilar insulin glargine opportunity in US

22-Jan-2022

external_link-01
The Medicine Box: Kiran Mazumdar-Shaw on biosimilar interchangeable status for Biocon’s diabetes drug

25-Nov-2021

external_link-01
Biocon Biologics, Viatris confirm offering steep savings on long-acting insulin through Walgreens Prescription Savings Club

19-Nov-2021

external_link-01
Walgreens to sell Biocon’s insulin Semglee in the U.S.

19-Nov-2021

external_link-01
Biocon Biologics, Viatris launch interchangeable insulin biosimilar for US

 16-Nov-2021

external_link-01
Biocon Rating: Hold – Vaccines to complement biosimilar portfolio

 20-Sep-2021

external_link-01
Biocon Biologics, Serum Institute Life Sciences announce strategic alliance

 20-Sep-2021

external_link-01
Interchangeable insulin to help us compete with big insulin makers: Kiran Mazumdar-Shaw

 29-Aug-2021

external_link-01
Shreehas Tambe named Deputy CEO of Biocon Biologics

 02-Mar-2021

external_link-01
Biocon Biologics, Viatris get CHMP nod for Abevmy

 02-Mar-2021

external_link-01
Biocon Biologics to partner with International Diabetes Federation

 16-Feb-2021

external_link-01
Biocon Biologics Receives USD 150 Million Capital Injection from Goldman Sachs

08-Nov-2020

external_link-01
India-based company brings affordable insulin to 2 PH towns

23-Oct-2020

external_link-01
India’s Biocon secures approval to use drug on coronavirus patients

 11-July-2020

external_link-01
Biosimilar drugs can help us reach $1 billion target soon

16-Jun-2020

external_link-01
Kiran Mazumdar-Shaw named EY World Entrepreneur of 2020

 06-Jun-2020

external_link-01
Covid provides larger opportunity to shape the biosimilar landscape

 19-May-2020

external_link-01
Biocon’s cancer biosimilar gets US FDA acceptance for review

 10-Mar-2020

external_link-01
Biocon chief is EY entrepreneur for 2019

 22-Feb-2020

external_link-01
Biocon Biologics Eyes $200M. Plans IPO in 2 Yrs: Mazumdar-Shaw

 27-Jan-2020

external_link-01
Biocon, partner Mylan launch oncology biosimilar trastuzumab in US

11-Dec-2019

external_link-01
Biocon, Mylan get nod for pegfilgrastim drug

28-Nov-2019

external_link-01
Indian company makes it to top 10 best employers in biotech category

30-Oct-2019

external_link-01
Insulin at ₹7 will be a gamechanger for us

26-Oct-2019

external_link-01
Life-enabling product like insulin should be made affordable: Shaw

28-Sep-2019

external_link-01
Biocon plans to halve insulin prices

27-Sep-2019

external_link-01
Biocon sets $1 billion target for biologics business

25-Oct-2019

external_link-01
Biocon subsidiary acquires Pfizer’s R&D facility in Chennai

25-Sep-2019

external_link-01
Ramp-up of biosimilar portfolio to boost Biocon

22-Aug-2019

external_link-01
Our aim is to be a global leader in biosimilars biz: Biocon Biologics CEO

 30-Jul-2019

external_link-01
Biosimilars, research key drivers for Biocon

 18-Jun-2019

external_link-01
Trastuzumab’s US launch will be a big opportunity for Biocon-Mylan: Shaw

 18-Jun-2019

external_link-01
Biocon’s Bengaluru biologics units get European agency nod

 15-Jun-2019

external_link-01
The First Lady of Biotech

 08-Jun-2019

external_link-01
Canada clears Mylan & Biocon’s Biosimilar

 23-May-2019

external_link-01
Biocon drug gets commercial rights to global markets

 09-May-2019

external_link-01
Biosimilars to help Biocon hit $1bn revenue in FY20

 30-Apr-2019

downloadicon-01
Kiran Mazumdar-Shaw conferred with honorary doctorate from Deakin University, Australia

 18-Apr-2019

external_link-01
Research must be promoted in colleges

 08-Apr-2019

external_link-01
ET Prime celebrates Women’s Excellence in Business & Innovation

 05-Apr-2019

external_link-01
Breakthrough innovation is taking place but we’re not leveraging it

 05-Apr-2019

external_link-01
Kiran Mazumdar-Shaw conferred with Honorary Doctorate

 04-Apr-2019

external_link-01
Biocon Biologics India appoints Dr. Christiane Hamacher as CEO

 01-Apr-2019

external_link-01
Biocon chief stresses on gender equality

 29-Mar-2019

external_link-01
Kiran back as Infy’s independent director

 19-Mar-2019

external_link-01
Govt Should Scale Up Philanthropic Capital

 18-Mar-2019

external_link-01
Cost of select insulin increases up to 20%

 15-Mar-2019

external_link-01
Role of Indian women in Science & Technology

 12-Mar-2019

external_link-01
The growing share of biosimilars revenue is doing wonders for our business

 11-Mar-2019

external_link-01
Biosimilars offer a huge opportunity for Biocon

 08-Mar-2019

external_link-01
Future jobs will be different: Shaw

 07-Mar-2019

external_link-01
Pharma specialist new CEO of Biocon Biologics

 03-Mar-2019

external_link-01
Hamacher is CEO of Biocon Biologics

 02-Mar-2019

external_link-01
In bid to curb profiteering, govt caps margins of 42 cancer drugs

 28-Feb-2019

external_link-01
Shortage of women for leadership roles

 23-Feb-2019

external_link-01
Biocon’s Trastuzumab receives approvals in EU

 13-Feb-2019

external_link-01
Kiran Mazumdar-Shaw elected member of US-based NAE

 09-Feb-2019

external_link-01
Biosimilars make Biocon stand apart

 28-Jan-2019

external_link-01
Share